Golden Cross
3日前
$COSM 🗞️ Cosmos Health Achieves Pan-European Distribution for Sky Premium Life Across All 27 EU Member States Through Leading E-Commerce Platform Skroutz
🔗 https://markets.financialcontent.com/stocks/article/gnwcq-2026-6-4-cosmos-health-achieves-pan-european-distribution-for-sky-premium-life-across-all-27-eu-member-states-through-leading-e-commerce-platform-skroutz
CHICAGO, June 04, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ: COSM), a diversified, vertically integrated global healthcare group, today announced that its proprietary brand, Sky Premium Life, is now available for shipment across all 27 European Union Member States through Skroutz, significantly expanding the brand’s international reach.
A total of 96 Sky Premium Life products are now accessible to consumers across all 27 European Union Member States through Skroutz, with shipments reaching key markets across Western Europe, Northern Europe, and Central and Eastern Europe. The countries covered include Austria, Belgium, Bulgaria, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, and Sweden.
Skroutz is one of the leading e-commerce platforms in Southeast Europe, connecting millions of consumers with a wide network of merchants and brands. Its cross-border capabilities enable efficient distribution and localized access to products across multiple European markets, making it a strategic channel for international expansion.
The Company believes that this expanded distribution footprint further strengthens the global positioning of the Sky Premium Life brand, enabling broader market penetration and increased accessibility to its portfolio of premium nutraceutical and wellness products.
Greg Siokas, CEO of Cosmos Health, stated: "The expansion of Sky Premium Life across all 27 EU Member States through Skroutz represents a key milestone in our international growth strategy. By leveraging Skroutz’s cross-border infrastructure, we are able to efficiently scale distribution and reach consumers across Europe. This initiative further enhances our brand visibility and supports our continued focus on driving revenue growth and expanding our global presence.”
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
US Market News
3週前
Cosmos Health Announces Expiration of 4,874,126 Series B Warrants Unexercised; ~38% of Total Outstanding WarrantsMay 21, 2026 2:20 PM
ACCESS NewswireNo dilution to existing shareholdersReduction in total outstanding warrant overhangSimplifies capital structure CHICAGO, IL / ACCESS Newswire / May 21, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that its Series B warrants expired unexercised in accordance with their original terms at 5:00 p.m. New York City time on May 19, 2026.The expired warrants carried an exercise price of $0.95 per share and represented 4,874,126 warrant shares - equal to approximately 38% of the Company's total outstanding warrants.Their expiration eliminates this overhang with no new shares issued and no dilution to existing shareholders, while meaningfully simplifying the Company's capital structure going forward.Greg Siokas, Chief Executive Officer of Cosmos Health, stated: "The expiration of these warrants is a positive development for our shareholders. The elimination of 4.87 million warrant shares - representing almost 38% of our total outstanding warrants - meaningfully reduces our dilution overhang and reflects our ongoing commitment to a cleaner, more shareholder-friendly capital structure. As we continue to execute on our strategy, we believe a simplified capital structure better positions the Company for long-term value creation."About Cosmos Health Inc.Cosmos Health Inc. (NASDAQ:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.Forward-Looking StatementsWith the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans," and similar expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could," generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company's control, including, but not limited to: the Company's ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company's business, operations, and the economy in general; and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any obligation to update or revise forward-looking statements, whether as a result of any new information, future events, or otherwise.Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.comSOURCE: Cosmos Health Inc.View the original press release on ACCESS NewswireOriginal: Cosmos Health Announces Expiration of 4,874,126 Series B Warrants Unexercised; ~38% of Total Outstanding Warrants
US Market News
3週前
Cosmos Health Reports Q1 2026 Results: Revenue Up 31% to $17.9M, New Q1 Record; Total Liabilities Reduced by $4.5M; Stockholders' Equity Up 7.6%; Cash of $2.2M; Record Momentum Continues into Q2 with U.S. Expansion UnderwayMay 21, 2026 9:15 AM
ACCESS NewswireRecord Q1 revenue of $17.9M, up 31% from $13.71 million in Q1 2025, reflecting strength across all core segmentsTotal liabilities decreased by $4.5M, or 9.6%, driven by a substantial reduction in convertible note and credit facility balancesStockholders' equity increased by $1.4M, or 7.6%, with the liabilities-to-assets ratio improving by 370 basis pointsAdjusted EBITDA near breakeven as increased revenue was offset by strategic investments to support global growthRecord momentum continues into Q2 2026 with U.S. expansion actively underway CHICAGO, IL / ACCESS Newswire / May 21, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Financial HighlightsIncome StatementCosmos Health delivered the highest Q1 revenue in Company history with continued progress toward adjusted profitability, reflecting broad-based commercial strength - over 75 new pharmacies added at CosmoFarm, growing Sky Premium Life order activity across multiple markets, and expanded contract manufacturing agreements at Cana Laboratories.Revenue was $17.93 million, an increase of 30.7% from $13.71 million in Q1 2025, reflecting strong sales momentum across all core divisions.Adjusted revenue was $18.40 million, up 34.2% year-over-year, reflecting a $470,601 sales discount reversal.Gross profit was $1.38 million in Q1 2026, compared to $2.05 million in Q1 2025, reflecting a revenue mix shift toward wholesale distribution activity at CosmoFarm, compounded by the aforementioned sales discount adjustment.Adjusted gross profit was $1.85 million, reflecting the sales discount reversal applied to revenue.Total operating expenses increased to $3.57 million in Q1 2026, compared to $2.88 million in Q1 2025, reflecting strategic investments in personnel, infrastructure, technology, and AI-driven efficiencies to support global growth initiatives.Net income (loss) was ($2.81 million) in Q1 2026, compared to ($0.82 million) in Q1 2025. The increase is driven principally by $1.15 million of non-cash, non-operational items:$390,350 in non-cash interest on convertible facilities$442,439 in digital asset mark-to-market losses$313,157 in foreign currency translation lossesAdjusted EBITDA was ($229,596) in Q1 2026, near breakeven, as increased revenue was offset by higher expenses reflecting the Company's ongoing investments in global growth initiatives.Adjusted Net Income (Loss) was ($996,502), driven by $766,906 in interest expense incurred in support of the Company's growth investments.Balance SheetCosmos Health continued to improve its balance sheet in Q1 2026, with active debt reduction and working capital optimization driving an improvement in the liabilities-to-assets ratio to 68.2% from 71.9% at year-end 2025.Total assets were $62.37 million as of March 31, 2026, compared to $65.48 million at December 31, 2025, reflecting a diversified asset base with solid liquidity, a strong inventory position, and a significant real estate and intellectual property portfolio.Liquid assets totaled $4.3 million, comprising cash and cash equivalents of $2.2 million as well as digital assets and marketable securities of $2.1 million.Total liabilities decreased by $4.51 million, or 9.6%, to $42.54 million as of March 31, 2026, from $47.05 million at December 31, 2025, driven by a substantial reduction in convertible note and credit facility balances.Total stockholders' equity increased by $1.40 million, or 7.6%, to $19.83 million as of March 31, 2026, up from $18.42 million at December 31, 2025.Management CommentaryGreg Siokas, CEO of Cosmos Health, stated: "Q1 2026 was a record Q1 for Cosmos Health, with revenue of $17.93 million, up 31% year-over-year and 34% on an adjusted basis, reflecting broad-based commercial momentum across every major division - record distribution volumes at CosmoFarm, continued global expansion of Sky Premium Life, and new contract manufacturing agreements at Cana Laboratories.This momentum is continuing into Q2 2026, and we are focused on sustaining it well beyond this year. We believe Cosmos Health is entering a new phase of growth, driven by strategic investments across our organization - in personnel, facilities, infrastructure, technology, and AI-driven efficiencies - to support our global expansion plans, strengthen our R&D pipeline, and build the foundation for long-term sustainable value creation. A key pillar of this growth is our entry into the lucrative U.S. nutraceuticals market through the 18 Series platform. Adjusted EBITDA is near breakeven, and we expect it to turn positive as our growth investments drive meaningful returns and revenues continue to scale.At the same time, we have been disciplined in managing our balance sheet. We reduced total liabilities by $4.5 million in a single quarter, a 9.6% reduction, driven by a substantial reduction in convertible note and credit facility balances. Meanwhile, stockholders' equity increased by 7.6%, our liabilities-to-assets ratio improved by 370 basis points, and our liquidity position remains solid, with $4.3 million in liquid assets including cash of $2.2 million, to support our growth plans.Q1 2026 is an early indication of what we believe will be a period of significant growth for Cosmos Health, and we look forward to updating our shareholders as this story continues to unfold."UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
Three Months Ended March 31,
2026 2025 (in $)
GAAP Figures
REVENUE 17,927,892 13,712,528 GROSS PROFIT 1,381,171 2,049,799 TOTAL OPERATING EXPENSES (3,565,350) (2,882,944)GAIN (LOSS) FROM OPERATIONS (2,184,179) (833,145)TOTAL OTHER INCOME (EXPENSE), NET (621,244) 15,048 NET GAIN (LOSS) (2,805,423) (818,097)
NON-GAAP Figures* ADJUSTED REVENUE 18,398,493 13,712,528 ADJUSTED GROSS PROFIT 1,851,772 2,049,799 ADJUSTED EBITDA (229,596) 373,119 ADJUSTED NET INCOME (LOSS) (996,502) 277,338 (*) See "Definitions of Non-GAAP Measures" and "Reconciliation of Non-GAAP Measures" sections herein for an explanation and reconciliations of non-GAAP measures used throughout this release.Definitions of Non-GAAP MeasuresWe collect and analyze operating and financial data to evaluate the health of our business and assess our performance. In addition to Revenue, Gross Profit, Income (Loss) from Operations and Net Income (Loss) under GAAP, we use: Adjusted Revenue, Adjusted Gross Profit, EBITDA, Adjusted EBITDA, and Adjusted Net Income (Loss). We have included these non-GAAP financial measures because they are key measures used by our management to evaluate our operating performance. Accordingly, we believe that these non-GAAP financial measures provide useful information to investors and others in understanding and evaluating our operating results in the same manner as our management team and Board of Directors. Therefore, these non-GAAP financial measures are presented here. Our calculation of these non-GAAP financial measures may differ from similarly titled non-GAAP measures, if any, reported by our peer companies. These non-GAAP financial measures should not be considered in isolation from, or as substitutes for, financial information prepared in accordance with GAAP.Adjusted RevenueWe define Adjusted Revenue as GAAP Revenue adjusted to include revenues subject to revenue recognition timing adjustments. Adjusted Revenue is supplemental in nature and is not meant as a substitute for Revenue prepared in accordance with GAAP.Adjusted Gross ProfitWe define Adjusted Gross Profit as GAAP Gross Profit adjusted for the same revenue recognition timing adjustments described under Adjusted Revenue above. Adjusted Gross Profit is supplemental in nature and is not meant as a substitute for Gross Profit prepared in accordance with GAAP.Adjusted EBITDAWe define Adjusted EBITDA as Income (Loss) before Income Taxes, excluding (i) depreciation and amortization expense, (ii) interest income (expense), net, (iii) non-cash interest expense, (iv) stock-based compensation expense, (v) non-recurring and extraordinary items, (vi) other income (expense), net, (vii) gain (loss) on equity investments and digital assets, net, (viii) change in fair value of derivative liability and convertible notes, (ix) foreign currency transaction, net, and (x) sales discount reversals.We have included Adjusted EBITDA because it is a key measure used by our management team to evaluate our operating performance, generate future operating plans, and make strategic decisions. Accordingly, we believe that Adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results in the same manner as our management team and Board of Directors. In addition, it provides a useful measure for period-to-period comparisons of our business, as it removes the effect of certain non-cash expenses and non-recurring and extraordinary items.For investors to better evaluate the Company's performance and compare results across reporting periods, Cosmos Health provides a reconciliation of GAAP to non-GAAP financial measures. These adjustments exclude certain non-cash and non-recurring items, including stock-based compensation, non-cash interest expense, changes in the fair value of derivatives and convertible notes, gains or losses on digital assets, foreign currency transactions, sales discount reversals, and other non-operating or non-recurring items, as applicable and as further described above.The presentation of the Company's non-GAAP financial measures is not meant to be considered in isolation or as a substitute for the Company's financial results prepared in accordance with GAAP, and the Company's non-GAAP measures may be different from non-GAAP measures used by other companies. Adjusted EBITDA has limitations as a financial measure, should be considered as supplemental in nature, and is not meant as a substitute for the related financial information prepared in accordance with GAAP.Adjusted Net Income (Loss)We define Adjusted Net Income (Loss) as Adjusted EBITDA (see above) adding provision for income taxes and deducting interest expense.Adjusted Net Income (Loss) has limitations as a financial measure, should be considered as supplemental in nature, and is not meant as a substitute for the related financial information prepared in accordance with GAAP.Reconciliation of Non-GAAP Measures
Adjusted Revenue, Adjusted Gross Profit, Adjusted EBITDA & Adjusted Net Income (Loss)The following table presents reconciliations of Adjusted Revenue, Adjusted Gross Profit, Adjusted EBITDA and Adjusted Net Income (Loss) to the most directly comparable GAAP financial measures for each of the periods indicated.
Three Months Ended March 31,
2026 2025 (in $)
REVENUE 17,927,892 13,712,528 Sales discount reversal 470,601 - ADJUSTED REVENUE 18,398,493 13,712,528
GROSS PROFIT 1,381,171 2,049,799 Sales discount reversal 470,601 - ADJUSTED GROSS PROFIT 1,851,772 2,049,799
INCOME (LOSS) BEFORE INCOME TAXES (2,805,423) (818,097)Adjustments (add back): Depreciation and amortization expense 348,179 320,439 Interest (income) / expense, net 766,906 95,781 EBITDA (1,690,338) (401,877)
Sales discount reversal 470,601 -
Non-recurring and extraordinary items 245,116 135,621 Stock-based compensation 535,786 556,611 Other income (expense), net (86,161) 261,730 Change in fair value of derivative liability & convertible notes (471,448) - (Gain) / loss on equity investments & digital assets, net 453,691 (3,142)Foreign currency transaction, net 313,157 (175,824)ADJUSTED EBITDA (229,596) 373,119 Interest income / (expense), net (766,906) (95,781)ADJUSTED NET INCOME (LOSS) (996,502) 277,338 CONDENSED CONSOLIDATED BALANCE SHEET DATA
March 31, 2026 December 31, 2025 September 30, 2025 (in $) (Unaudited) (Audited) (Unaudited) ASSETS
Cash & cash equivalents 2,158,921 3,459,893 4,633,660 Inventory 5,650,458 5,778,142 5,683,662 Accounts receivable, prepaid expenses and other current assets 28,594,752 28,662,583 25,952,190 Property and equipment, net 10,280,203 10,578,858 10,664,820 Goodwill and intangible assets, net 7,225,011 7,569,695 7,960,633 Loans receivable 3,605,388 3,633,839 7,666,483 Other noncurrent assets 4,854,278 5,794,508 6,931,310 TOTAL ASSETS 62,369,011 65,477,518 69,492,758
LIABILITIES AND STOCKHOLDERS' EQUITY Accounts payable and accrued expenses 15,689,061 17,412,973 15,198,777 Other current liabilities 6,701,051 6,047,940 5,505,549 Lines of credit 7,856,208 9,177,684 7,584,786 Notes payable 9,954,812 11,485,084 15,956,667 Other non-current and finance/lease liabilities 2,341,520 2,929,208 2,112,095 Stockholders' and mezzanine equity 19,826,359 18,424,629 23,134,885 TOTAL LIABILITIES AND STOCKHOLDERS'/MEZZANINE EQUITY 62,369,011 65,477,518 69,492,758 About Cosmos Health Inc.Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available atwww.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr,www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.Forward-Looking StatementsWith the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans," and similar expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could," generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company's control, including, but not limited to: the Company's ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company's business, operations, and the economy in general; the Company's ability to successfully develop and commercialize its proprietary products and technologies; changes in interest rates; changes in foreign currency exchange rates, commodity or other price inflation and deflation; our ability to issue debt on terms and at rates acceptable to us; the impact and expected outcome of investigations, inquiries, claims, and litigation; the challenges of operating in international markets; the adequacy of insurance coverage; the effect of accounting charges and of adopting certain accounting standards; the impact of legal and regulatory changes, including changes to tax laws and regulations; guidance for fiscal 2026 and beyond and financial outlook. Forward-looking statements are based on currently available information and our current assumptions, expectations and projections about future events. You should not rely on our forward-looking statements. These statements are not guarantees of future performance and are subject to future events, risks and uncertainties - many of which are beyond our control, dependent on the actions of third parties, or currently unknown to us - as well as potentially inaccurate assumptions that could cause actual results to differ materially from our historical experience and our expectations and projections. These risks and uncertainties include, but are not limited to, those described from time to time in our periodic reports filed with the SEC and available at the SEC's website (www.sec.gov). There also may be other factors that we cannot anticipate or that are not described herein, generally because we do not currently perceive them to be material. Such factors could cause results to differ materially from our expectations. Forward-looking statements speak only as of the date they are made, and we do not undertake to update these statements other than as required by law. You are advised, however, to review any further disclosures we make on related subjects in our filings with the Securities and Exchange Commission and in our other public statements.Investor Relations Contact:BDG Communications
cosm@bdgcommunications.comSOURCE: Cosmos Health Inc.View the original press release on ACCESS NewswireOriginal: Cosmos Health Reports Q1 2026 Results: Revenue Up 31% to $17.9M, New Q1 Record; Total Liabilities Reduced by $4.5M; Stockholders' Equity Up 7.6%; Cash of $2.2M; Record Momentum Continues into Q2 with U.S. Expansion Underway
US Market News
4週前
Cosmos Health Announces Withdrawal of Registration Statement on Form S-1May 12, 2026 10:15 AM
ACCESS NewswireCHICAGO, IL / ACCESS Newswire / May 12, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it has filed with the U.S. Securities and Exchange Commission (the "SEC") a request for withdrawal of the Company's Registration Statement on Form S-1 (File No. 333-283910), originally filed on December 18, 2024 and last amended on June 3, 2025 (the "Registration Statement"), as the Company no longer intends to pursue a public offering under the Registration Statement at this time.The Registration Statement has not been declared effective and no securities of the Company were sold in connection with the offering.This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of these securities and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful.About Cosmos Health Inc.Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.Forward-Looking StatementsWith the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans," and similar expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could," generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company's control, including, but not limited to: the Company's ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company's business, operations, and the economy in general; and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any obligation to update or revise forward-looking statements, whether as a result of any new information, future events, or otherwise.Investor Relations Contact:BDG Communications
cosm@bdgcommunications.comSOURCE: Cosmos Health Inc.View the original press release on ACCESS NewswireOriginal: Cosmos Health Announces Withdrawal of Registration Statement on Form S-1
US Market News
4週前
Cosmos Health Projects Over $3.2 Million in Incremental Annual Revenue from Fort18 in the United States Within 12-18 MonthsMay 11, 2026 2:25 PM
ACCESS NewswireCHICAGO, IL / ACCESS Newswire / May 11, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced it is projecting Fort18™ to generate over $3.2 million in incremental annual U.S. revenue within the next 12 to 18 months, based on its current commercialization strategy and internal assumptions. Fort18™ is the latest addition to the Company's "18 Series," a growing portfolio of science-based nutraceutical products. Formulated with a proprietary botanical blend evaluated in published clinical research, Fort18™ enters the U.S. sexual health supplement category targeting men's sexual stamina and endurance. The product is expected to launch commercially in June 2026.The Company's projection is underpinned by a staged rollout beginning with direct-to-consumer e-commerce, with planned expansion into selected retail channels over time. The forecast incorporates internal assumptions around pricing, anticipated sales volumes, repeat purchase behavior, and distribution growth, and remains subject to the continued execution of the Company's commercialization plans.According to Grand View Research, the global sexual health supplement market was valued at $3.52 billion in 2023 and is projected to nearly double to $7.02 billion by 2030, growing at a CAGR of 10.4%. The United States stands as one of the largest individual markets globally, estimated at $965.8 million in 2023 and forecast to reach $1.93 billion by 2030, according to Grand View Horizon.Greg Siokas, Chief Executive Officer of Cosmos Health, stated: "Fort18™ marks our entry into the U.S. men's wellness category - a large and rapidly growing market driven by increasing consumer demand for science-supported products. We believe it has the potential to become a meaningful revenue contributor to our nutraceutical portfolio as we scale distribution."About Cosmos Health Inc.Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.No statement made herein has been evaluated by the U.S. Food and Drug Administration. Any product described above is not intended to diagnose, treat, cure, or prevent any disease.Forward-Looking StatementsWith the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans," and similar expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could," generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company's control, including, but not limited to: the Company's ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company's business, operations, and the economy in general; and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any obligation to update or revise forward-looking statements, whether as a result of any new information, future events, or otherwise.Investor Relations Contact:BDG Communications
cosm@bdgcommunications.comSOURCE: Cosmos Health Inc.View the original press release on ACCESS NewswireOriginal: Cosmos Health Projects Over $3.2 Million in Incremental Annual Revenue from Fort18 in the United States Within 12-18 Months
US Market News
1月前
Cosmos Health Introduces Fort18 in the United States - A Men's Sexual Stamina Supplement Expanding the 18 Series into Men's WellnessMay 6, 2026 10:35 AM
ACCESS NewswireScience-based men's wellness: Fort18™ is formulated with a proprietary five-ingredient botanical blend intended to support men's sexual staminaLarge and growing market: The U.S. sexual health supplement market is projected to reach $1.93 billion by 2030Expanding the 18 Series: Fort18™ joins Noor18™, Liv18™, and Cur18™ - advancing the target of 18 science-based products spanning key health categories CHICAGO, IL / ACCESS Newswire / May 6, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the introduction of Fort18™ in the United States - a men's sexual stamina supplement formulated with a proprietary blend of botanical extracts and nutrients that has been evaluated in published clinical research.Fort18™ is the latest addition to the Company's "18 Series," entering a large and growing market with a science-based formulation supported by published human clinical data. It is estimated that a significant proportion of men globally may experience reduced sexual stamina and endurance, and are increasingly seeking solutions supported by clinical research.Published Clinical ResearchPublished clinical research on the active ingredient (Journal of Medicinal Food, September 2020) has reported a 5.1-fold improvement in endurance over the placebo group over eight weeks, with results observed as early as Week 4 of the study. The following summarizes key findings from published clinical research on the active ingredient:ParameterDetailStudy designRandomized, double-blind, placebo-controlledPopulation60 healthy men, aged 18-60, experiencing reduced sexual staminaDuration8 weeksKey findingPublished research has reported a 5.1-fold improvement in endurance over the placebo groupOnsetResults observed as early as Week 4 of the published studySafety observationsNo significant changes noted in vital signs or blood, serum, or urine markers during the study periodIP statusExclusive and patent-protected standardization fingerprint, held by ingredient supplierFormulationFort18™ is formulated with a proprietary blend of five botanical extracts and nutrients - L-arginine and extracts of mucuna, fenugreek, ashwagandha, and artichoke - collectively standardized to a minimum of 20% saponins and 1.5% total flavonoids. The blend is designed to collectively support the hormonal, neuronal, and vascular pathways associated with male sexual stamina and endurance, drawing on botanical ingredients with a long history of use in traditions such as Ayurveda and Traditional Chinese Medicine:Artichoke leaf extract: supports healthy blood flow through nitric oxide-related pathwaysFenugreek seed extract: associated with support of arousal, energy, and stamina in published researchAshwagandha root extract: an adaptogenic botanical supporting a healthy stress response and nervous system functionMucuna seed extract: studied for its support of dopamine-related pathways and male wellnessL-Arginine: an amino acid associated with vascular support and healthy blood flow through nitric oxide productionThe formulation's standardization fingerprint is exclusive and patent-protected. Fort18™ is formulated at 500mg twice per day - consistent with the dose evaluated in published clinical research.Market ContextAccording to Grand View Research, the global sexual health supplement market was estimated at $3.52 billion in 2023 and is projected to reach $7.02 billion by 2030, growing at a CAGR of 10.4%. The United States is one of the largest individual markets globally, accounting for an estimated 27.4% of the global market - estimated at $965.8 million in 2023 and projected to reach $1.93 billion by 2030, representing a near-doubling of market size over the period, per Grand View Horizon. Male consumers represent more than 55% of the global consumer base for sexual health supplements, per Market.us.Greg Siokas, CEO of Cosmos Health, stated: "The men's wellness category represents a significant and growing market opportunity, and one where consumers are increasingly seeking products with credible scientific substantiation. The introduction of Fort18™ - formulated with a proprietary botanical blend backed by published clinical research - is an important step in the expansion of our 18 Series into the United States, and we believe it has the potential to become a meaningful contributor to our broader nutraceutical portfolio."About the 18 SeriesFort18™ is the latest addition to the Company's "18 Series" - a portfolio of science-based nutraceutical products where every product is designed to meet three defined criteria: a proprietary ingredient backed by published research, published clinical studies supporting its intended use, and dosing consistent with published clinical research. The Company notes that these criteria reflect a rigorous approach to ingredient selection consistently applied across the portfolio.The Company has a strategic target of 18 products spanning key health categories. In addition to Fort18™, other current 18 Series products include Noor18™ (marine collagen, anti-aging; proprietary formulation held by ingredient supplier), Liv18™ (liver fat support; active ingredient covered by a granted patent held by ingredient supplier), and Cur18™ (next-generation curcumin; active ingredient utilizing patent-protected proprietary technology held by ingredient supplier).Cosmos Health sources its active ingredients from established suppliers and all products are manufactured in the United States under applicable quality and regulatory standards.These products are dietary supplements. Statements regarding these products have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.About Cosmos Health Inc.Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.Forward-Looking StatementsWith the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans," and similar expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could," generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company's control, including, but not limited to: the Company's ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company's business, operations, and the economy in general; and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any obligation to update or revise forward-looking statements, whether as a result of any new information, future events, or otherwise.Investor Relations Contact:BDG Communications
cosm@bdgcommunications.comSOURCE: Cosmos Health Inc.View the original press release on ACCESS NewswireOriginal: Cosmos Health Introduces Fort18 in the United States - A Men's Sexual Stamina Supplement Expanding the 18 Series into Men's Wellness
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
jimr1717
21時間前
resx18
3日前
Trooperstocks
3日前
fliper
4日前
EpicSage
4日前
glenn1919
4日前
Monroe1
5日前
メールアドレスで登録
